https://www.selleckchem.com/pr....oducts/nivolumab.htm
Patients who received any cirAE treatment had improved progression-free survival [hazard ratio (HR) 0·59, P=0·001] and overall survival (HR 0·58, P=0·007) compared with those who did not. CirAEs evaluated by dermatologists were significantly more likely to be treated than cirAEs that were not referred, and patients who received any treatment for a cirAE had improved survival outcomes. CirAEs evaluated by dermatologists were significantly more likely to be treated than cirAEs that were not referred, and patients who received any treatm
Like
Comment
Share
